All the information on this page is sourced for Thomson Reuters Cortellis for Competitive Intelligence TM, find out more about Cortellis for Competitive Intelligence and take a free two week trial to see what Cortellis for Competitive Intelligence can do for you.
Content last updated January 30, 2012.
Erlotinib (Tarceva) is an orally active, selective EGFR tyrosine kinase inhibitor and just one of the many drugs covered in Thomson Reuters Cortellis for Competitive Intelligence. In addition to the Drug Report summary information below, in Cortellis for Competitive Intelligence, you will see the drug overview information, news, deals, development status, literature evaluations, SWOT analysis, patent position and sales and market share data. There are over 40,000 of these Drug Reports in Cortellis for Competitive Intelligence.
Cortellis for Competitive Intelligence combines the same premier information used by the world's leading pharmaceutical companies from products such as Thomson Reuters Pharma TM and Thomson Reuters Partnering TM (formerly IDDB). Featuring daily updates and timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.
All Cortellis for Competitive Intelligence content is subject to an exhaustive editorial review process conducted by scientists, Pharma professionals, regulatory experts, and generics specialists. It is also updated regularly, so you get the most accurate and up-to-date information on the pharmaceutical data that matters to you.
Take a two week trial of Cortellis for Competitive Intelligence and see what it can do for you.
|Company||OSI Pharmaceuticals Inc (Astellas Pharma Inc)|
|Highest dev status||Launched|
|Therapy areas||Esophagus tumor; Glioma; Non-small-cell lung cancer; Renal cell carcinoma; Hepatocellular carcinoma; Pancreas tumor; Psoriasis; Breast tumor; Head and neck tumor; Hepatobiliary system tumor; Cancer; Solid tumor; Ovary tumor; Colorectal tumor|
|Actions||Systemic antipsoriatic product; Anticancer; EGFR family tyrosine kinase receptor inhibitor; Anticancer protein kinase inhibitor; Epidermal growth factor antagonist|
|Technologies||Oral formulation; Tablet formulation; Film coating; Small molecule therapeutic|
|Target||EGFR family tyrosine kinase receptor;Epidermal growth factor receptor|
|Reason for update||Minor editorial amendment|